Long-term efficacy and safety of luspatercept for the treatment of anaemia in patients with transfusion-dependent β-thalassaemia (BELIEVE): final results from a phase 3 randomised trial

Maria Domenica Cappellini(Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico), Alì Taher(American University of Beirut Medical Center), Luciana Moro Bueno(Bristol-Myers Squibb (Switzerland)), Abderrahim Khélif(Ente Ospedaliero Ospedali Galliera), Pencho Georgiev(University Multipurpose Hospital for Active Treatment "Sveti Georgi"), Antonis Kattamis, Natalia Holot(Bristol-Myers Squibb (United States)), Kevin H.M. Kuo(University Health Network), Hong-Keng Liew(Ente Ospedaliero Ospedali Galliera), Yinzhi Lai(Bristol-Myers Squibb (United States)), Abdalla Khalil(Rambam Health Care Campus), Thomas D. Coates(Children's Hospital of Los Angeles), Wen‐Ling Kuo(Chang Gung University), Vip Viprakasit(Siriraj Hospital), Lee-Ping Chew(Sarawak General Hospital), Adisak Tantiworawit(Ente Ospedaliero Ospedali Galliera), Loyse Felber Medlin(Bristol-Myers Squibb (Switzerland)), Martina Perin(Bristol-Myers Squibb (Switzerland)), Raffaella Origa(Ospedale Microcitemico), Ana Carolina Giuseppi(Bristol-Myers Squibb (United States)), P. Joy Ho(The University of Sydney)
The Lancet Haematology
February 10, 2025
Cited by 17


Related Papers